The estimated Net Worth of Detlef Albrecht is at least $724 millier dollars as of 1 September 2020. Detlef Albrecht owns over 1,000 units of Satsuma Pharmaceuticals stock worth over $23,333 and over the last 5 years he sold STSA stock worth over $0. In addition, he makes $701,149 as Chief Medical Officer at Satsuma Pharmaceuticals.
Detlef has made over 8 trades of the Satsuma Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of STSA stock worth $4,560 on 1 September 2020.
The largest trade he's ever made was exercising 1,000 units of Satsuma Pharmaceuticals stock on 1 September 2020 worth over $4,560. On average, Detlef trades about 636 units every 16 days since 2020. As of 1 September 2020 he still owns at least 21,212 units of Satsuma Pharmaceuticals stock.
You can see the complete history of Detlef Albrecht stock trades at the bottom of the page.
DR. Detlef Albrecht M.D. serves as Chief Medical Officer of the Company. Previously, Dr. Albrecht served in various roles at Armetheon, Inc., a pharmaceutical company, from May 2015 to June 2017, most recently as Head of Research and Development. He also served as President and Chief Executive Officer for Sorbent Therapeutics, Inc., a biopharmaceutical company, from August 2010 to July 2014. Dr. Albrecht received a Physician Degree and an M.D. from Rheinisch-Westfälische Technische Hochschule Aachen University.
As the Chief Medical Officer of Satsuma Pharmaceuticals, the total compensation of Detlef Albrecht at Satsuma Pharmaceuticals is $701,149. There are 2 executives at Satsuma Pharmaceuticals getting paid more, with John Kollins having the highest compensation of $1,368,100.
Detlef Albrecht is 59, he's been the Chief Medical Officer of Satsuma Pharmaceuticals since 2017. There are 3 older and 12 younger executives at Satsuma Pharmaceuticals. The oldest executive at Satsuma Pharmaceuticals, Inc. is Alan C. Mendelson J.D., 71, who is the Sec..
Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... et Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: